ONCOLYTIC VIRUS AND USE THEREOF

• Main Authors: JUNG, Byung Jin, KANG, Kyeong Tae, LEE, Jun Seung, LEE, Namhee, OH, Keunhee
• Format: Patent
• Language: English
• Published: 14.09.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present invention relates to an oncolytic virus and a use thereof and, specifically, to an oncolytic virus and a use thereof, wherein the oncolytic virus is designed to suppress the expression of thymidine kinase (TK) gene and include genes encoding granulocyte-macrophage colony-stimulating factor and a complement control protein. The oncolytic virus of the present invention maintains efficacy even upon intravenous injection and thus, can be applied to the therapy for various solid carcinomas and metastatic cancers as well as superficial solid tumors. In addition, having complement control proteins expressed on the surface thereof, the oncolytic virus of the present invention acquires resistance to the attack of the complement system in the body and is stable in blood and maintains stable oncolytic activity upon intravenous injection. The use of the virus at a reduced dose can minimize adverse effects of anticancer agents. Therefore, the anticancer virus of the present invention can be advantageously used for prevention or treatment of cancer.